38 results about "Tissue binding" patented technology

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

The present disclosure relates to the construction, expression, and selection of genes that encode novel Trp cage polypeptides with desirable cell and / or tissue binding properties, as well as the novel Trp cage polypeptides themselves. A polypeptide of this disclosure may contain all or part of amino acid sequence AAADX1YX2QWLX3X4X5GPX6SGRPPPX7 (SEQ ID NO: 4), wherein Xn represents an amino acid found in position n, the polypeptide comprising a tryptophan cage (Trp cage).

Surgeons may face the difficulty of preoperatively selecting the location for making an incision and intraoperatively identifying and differentiating targeted tissue for removal or for identification so that it is not removed along with neighboring or non-target tissue or so that neighboring or non-target tissue is not nicked, harmed, or removed accidentally. A tissue specific marker can include an aptamer or an affimer configured to bind to a pre-selected target tissue and one or more indicator elements coupled with the aptamer or the affimer. The one or more indicator elements produce a signal thereby allowing identification of the target tissue in a preoperative and operative manner.

The invention relates to contrast agents for medical science, in particular to a lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as a carrier and a preparation method and application of the lymph targeted nuclear magnetic resonance imaging contrast agent with the brown algal polysaccharide serving as the carrier. The macromolecular contrast agent high in water solubility is prepared by taking the brown algal polysaccharide as the carrier, taking mannose or mannose derivatives as a mannose receptor MBP (mannose binding protein) recognition group and taking paramagnetic metal ion chelates as a nuclear magnetic resonance imaging group. Lymph tissue binding force is increased, and combination of the mannose or mannose derivative group introduced into the synthetic contrast agent with mannose receptors enriched in lymph tissues is realized. In addition, after hypodermic injection of the contrast agent, lymph vessels and lymph glands are clearly developed under scanning of a nuclear magnetic resonance equipment, lymph gland signal enhancement rate of one side, with the contrast agent injected, of an animal body is remarkably increased while enhancement time is remarkably prolonged, distinct drawing and precise positioning of the lymph glands and the lymph vessels are realized, and a great significance to examination and diagnosis of lymphatic diseases is achieved.

The present invention relates to an improved endoscopic tissue apposition device having multiple suction ports. The invention permits multiple folds of tissue to be captured in the suction ports with a single positioning of the device and attached together by a tissue securement mechanism such as a suture, staple or other form of tissue bonding. The improvement reduces the number of intubations required during an endoscopic procedure to suture tissue or join areas of tissue together. The suction ports may be arranged in a variety of configurations on the apposition device to best suit the desired resulting tissue orientation. The inventive tissue apposition device may also incorporate tissue abrasion means to activate the healing process on surfaces of tissue areas that are to be joined by operation of the device to promote a more secure attachment by permanent tissue bonding.

The present invention discloses the method of preparation and use of soft tissue membranous structures into slip resistant membranes with regularly spaced surface projections on one side and concave depressions on the other side with perforations or without perforations which enhance vascular ingrowth and tissue incorporation.

The purpose of the present invention is to provide a light control agent and explore its application, and is expected to improve the tissue binding force and convenience of the existing biological glue material by providing a new reagent or material for biological damage or homeostasis. In one of embodiment, this invention provides an agent for repairing biological damage or homeostasis, wherein the agent comprises a natural biological macromolecule modified by the photo-responsive cross-linking group.

The invention provides a compound wound dressing with tissue binding performance and a preparation method of the compound wound dressing. Bioactive glass / albumin composite hydrogel at least comprisesbioactive glass, albumin, polyethylene glycol containing an electrophilic functional group and buffer solution, pH (potential of hydrogen) of the buffer solution ranges from 5.0 to 8.0, and the raw materials are mixed into gel to obtain the composite hydrogel. The composite hydrogel comprises albumin hydrogel and the bioactive glass loaded into the albumin hydrogel, the content of the albumin hydrogel is 95% or more, and the content of the bioactive glass is 5% or less.